The Exchange has sought clarification from Lupin Limited with respect to recent news item captioned Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices. The response from the Company is awaited.

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.9%Reaction day

₹1925.00

prior close

₹1871.30

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-1.3%-1.6% vs market

Pharmaceuticals peers, median of 149sector-2.0%-0.9% vs sector

On the reaction day the stock moved 1.6 pts less than Nifty Midcap 150 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.2

15m

+0.0

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.9-1.3-1.6-2.0-0.9

Next day

-2.2-0.1-2.0-1.5-0.7

-3.3-0.3-3.0-1.9-1.4

-3.8-1.2-2.6-3.8-0.1

+0.6-1.0+1.6-3.1+3.7

-0.2-2.4+2.2-4.1+3.9

+0.9-2.0+2.9-3.4+4.3

15d

+1.9+0.3+1.6-3.8+5.8

-1.0-1.2+0.1-4.2+3.2

+2.8-0.7+3.5-5.1+7.9

+3.8+4.0-0.2-4.2+8.0

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

NSE has asked Lupin Limited to clarify a recent news report that caused pharma stocks to fall. The article mentioned Trump sending letters to 17 global drug companies seeking lower drug prices. Lupin's response to the exchange is still awaited. Until the company responds, the exact impact on Lupin's business remains unconfirmed by management.

Likely market impact

The stock may remain under short-term pressure until the company provides its clarification. Investors should wait for Lupin's official response to understand any direct business impact, if any.